Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Endocrinology|February 15, 2003
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cellsJanice M Knowlden, Iain R Hutcheson, Helen E Jones, et al.
Histopathology|September 13, 2011
A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancerHany O Habashy, Desmond G Powe, Tarek M Abdel-Fatah, et al.
The Journal of Steroid Biochemistry and Molecular Biology|April 30, 2005
Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategiesR I Nicholson, I R Hutcheson, D Britton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combinationRobert I Nicholson, Iain R Hutcheson, Janice M Knowlden, et al.
Endocrine-Related Cancer|December 23, 2004
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cellsH E Jones, L Goddard, J M W Gee, et al.
Annals of the New York Academy of Sciences|July 4, 2002
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Breast Cancer Research : BCR|March 19, 2013
A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancerJohn F R Robertson, J Michael Dixon, D Mark Sibbering, et al.
British Journal of Cancer|February 21, 2019
MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancerMichael J G Milevskiy, Udai Gujral, Carolina Del Lama Marques, et al.
Endocrinology|September 10, 2003
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitroJ M W Gee, M E Harper, I R Hutcheson, et al.
Plos One|July 19, 2012
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerAndrew Stone, Fatima Valdés-Mora, Julia M W Gee, et al.
Pageof 7